Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Br J Psychiatry. 2009 Jun;194(6):541-6. doi: 10.1192/bjp.bp.108.055319.

    Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial.

    Source

    Norwegian Centre for Addiction Research, Kirkeveien 166, Oslo NO-0407, Norway. nikolaj.kunoe@medisin.uio.no

    Abstract

    BACKGROUND:

    Naltrexone has considerable potential in helping to prevent relapse in heroin dependency. A longer-lasting formulation for naltrexone treatment is desirable to further reduce non-adherence and relapse during treatment of opiate dependence.

    AIMS:

    To evaluate the safety and effectiveness of a 6-month naltrexone implant in reducing opioid use after in-patient treatment.

    METHOD:

    A group of 56 abstinence-oriented patients who completed in-patient treatment for opioid dependence were randomly and openly assigned to receive either a 6-month naltrexone implant or their usual aftercare. Drug use and other outcomes were assessed at 6-month follow-up.

    RESULTS:

    Patients receiving naltrexone had on average 45 days less heroin use and 60 days less opioid use than controls in the 180-day period (both P<0.05). Blood tests showed naltrexone levels above 1 ng/ml for the duration of 6 months. Two patients died, neither of whom had received an implant.

    CONCLUSIONS:

    Naltrexone implant treatment safely and significantly reduces opioid use in a motivated population of patients.

    Comment in

    PMID:
    19478295
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire
      Loading ...
      Write to the Help Desk